01 September 2023
: Case report 
Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma
Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy
Majed S. Alkharashi1AE, Rakan S. Al-Essa2ABCDEF*, Wael Otaif123ABEF, Ibrahim Algorashi4ADDOI: 10.12659/AJCR.940688
Am J Case Rep 2023; 24:e940688
Table 1. Summary of previously reported cases of ocular adverse effects in relation to the same chemotherapeutic agents.
| Author | Ocular surface adverse effect | Chemotherapeutic agent/etiology | Onset |
|---|---|---|---|
| Oh []13 | Atezolizumab/bladder cancer | Two months after initiating the treatment | |
| Bitton et al []14 | Atezolizumab/parotid adenocarcinoma | After 10 cycles | |
| Aschauer et al []15 | Atezolizumab/metastatic non-small-cell lung cancer | After 4 cycles | |
| Venkat et al []6 | Atezolizumab/advanced squamous cell carcinoma of the lung. | Five months after initiating the treatment | |
| Mito et al []17 | Atezolizumab/non-small-cell lung cancer | Three weeks after the first cycle of atezolizumab | |
| Biswas et al []20 | Bevacizumab/cutaneous melanoma | Occurring 11 days after the first cycle of bevacizumab | |
| Sherman et al []21 | Bevacizumab/glioblastoma | 3–18 months after initiating the treatment |